Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I/II Clinical Trial of the mTor Inhibitor RAD001 (Everolimus) in Combination With Lenalidomide (Revlimid) for Patients With Relapsed or Refractory Lymphoid Malignancy

NCT01075321 is registered in ClinicalTrials.gov with Mayo Clinic as lead sponsor.

NCT NCT01075321
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01075321 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I/II Clinical Trial of the mTor Inhibitor RAD001 (Everolimus) in Combination With Lenalidomide (Revlimid) for Patients With Relapsed or Refractory Lymphoid Malignancy
Lead sponsor
Mayo Clinic
Phase
Phase 1/2
Overall status
Completed
Start date
January 10, 2011
Completion date
February 13, 2020
Enrollment
58 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

adult nasal type extranodal nk/t-cell lymphoma, anaplastic large cell lymphoma, angioimmunoblastic t-cell lymphoma, extranodal marginal zone b-cell lymphoma of mucosa-associated lymphoid tissue, hepatosplenic t-cell lymphoma, nodal marginal zone b-cell lymphoma, peripheral t-cell lymphoma, post-transplant lymphoproliferative disorder, recurrent adult burkitt lymphoma, recurrent adult diffuse large cell lymphoma, recurrent adult hodgkin lymphoma, recurrent adult t-cell leukemia/lymphoma, recurrent grade 1 follicular lymphoma, recurrent grade 2 follicular lymphoma, recurrent grade 3 follicular lymphoma, recurrent mantle cell lymphoma, recurrent mycosis fungoides/sezary syndrome, splenic marginal zone lymphoma, waldenstrom macroglobulinemia